Skip to main content

RYEQO (Gedeon Richter Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
174 (255 working days)
Active ingredients
estradiol, norethisterone acetate, relugolix
Registration type

Ryeqo is indicated in adult women of reproductive age for:

  • treatment of moderate to severe symptoms of uterine fibroids,
  • symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (see section 5.1 PHARMACODYNAMIC PROPERTIES).

Help us improve the Therapeutic Goods Administration site